Incyte Corporation (INCY)
| Market Cap | 22.92B +36.5% |
| Revenue (ttm) | 5.82B +26.9% |
| Net Income | 1.61B +85.1% |
| EPS | 7.85 +79.7% |
| Shares Out | 202.70M |
| PE Ratio | 14.40 |
| Forward PE | 57.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,580,704 |
| Open | 113.98 |
| Previous Close | 113.27 |
| Day's Range | 112.02 - 114.57 |
| 52-Week Range | 84.02 - 132.60 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 129.50 (+14.53%) |
| Earnings Date | Oct 29, 2026 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $129.5, which is an increase of 14.53% from the latest price.
News
Incyte price target raised to $115 from $105 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Incyte (INCY) to $115 from $105 and keeps a Hold rating on the shares. The firm has updated its model…
Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte today announced eight winners of the 2026 MPN Heroes® annual recognition program. The program, now in its 14th year, pays tribute to individuals whose contrib...
Incyte price target raised to $114 from $109 at RBC Capital
RBC Capital raised the firm’s price target on Incyte (INCY) to $114 from $109 and keeps a Sector Perform rating on the shares as part of a broader research note…
Incyte to Report Third Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--3Q26 Earnings Announcement.
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval...
Incyte price target raised to $157 from $145 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Incyte (INCY) to $157 from $145 and keeps a Buy rating on the shares after having hosted a series of…
Incyte management to meet with Oppenheimer
Meeting to be held in New York on October 6 hosted by Oppenheimer.
Incyte price target raised to $123 from $120 at JPMorgan
JPMorgan analyst Jessica Fye raised the firm’s price target on Incyte (INCY) to $123 from $120 and keeps a Neutral rating on the shares.
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secreta...
Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged...
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progre...
FDA approves Incyte’s Atebrioz for fibrodysplasia ossificans progressiva
The U.S. Food and Drug Administration announced it has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older…
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio.
Specialised Therapeutics expands partnership with Incyte to include Opzelura
Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its existing partnership with Incyte (INCY) Biosciences International, an affiliate of Incyte, to commercialize...
Incyte Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The pipeline has advanced with new proof-of-concept and phase III data, supporting growth beyond 2029. Key programs in MPNs, solid tumors, and dermatology are progressing, with regulatory and commercial strategies in place. Acquisition of latarcibart and business development efforts aim to drive long-term value.
Incyte Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Pipeline assets have advanced to late-stage trials, with five key programs expected to drive post-2029 growth. Strategic R&D investment and selective business development support a 15–20% CAGR target, while upcoming data at ESMO and ASH will further clarify clinical and regulatory progress.
Incyte Transcript: Wells Fargo 21st Annual Healthcare Conference
Management outlined a dual strategy of core business growth and pipeline execution, with five key assets in late-stage development across hematology, oncology, and immunology. Franchise-building in GI oncology and hematology, innovative clinical programs, and disciplined business development are expected to drive significant revenue growth post-2029.
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at Upcoming Investor Conferences.
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental applicat...
Incyte initiated with a Buy at Canaccord
Canaccord initiated coverage of Incyte (INCY) with a Buy rating and $152 price target
Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital
Incyte (INCY) is expected to report updated data for KRAS G12D inhibitor ‘734, in combination with mFOLFIRINOX and GemNabP, at ESMO in October, with previous data showing “too little” to…
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) proudly recognizes and supports Incyte's Moments of Clarity campaign, a powerful storytelling initiative that highlights the l...
Incyte price target raised to $130 from $110 at Piper Sandler
Piper Sandler analyst Allison Bratzel raised the firm’s price target on Incyte (INCY) to $130 from $110 and keeps an Overweight rating on the shares following quarterly results. The firm…
Incyte price target raised to $104 from $99 at Bernstein
Bernstein raised the firm’s price target on Incyte (INCY) to $104 from $99 and keeps a Market Perform rating on the shares. The firm notes Incyte reported encouraging Q2 earnings.